GENENTECH INC

Genentech Inc has built its reputation as a pioneering developer of biotechnology-driven pharmaceutical preparations (SIC 2834) that blend human genetics, protein engineering, and clinical science to deliver breakthrough medicines for oncology, immunology, and rare diseases; its core products include monoclonal antibodies, targeted biologics, and companion diagnostics that large health systems, specialty clinics, and payers rely on to treat complex patient populations. The company partners with academic centers, research hospitals, and distributors to advance pipelines and ensure that dosing regimens reach the physicians responsible for high-acuity care, while also supporting nurses and pharmacists who manage infusion therapies in ambulatory and hospital settings. Standing at the intersection of scientific innovation and rigorous oversight, Genentech must manage material risks such as regulatory approvals, pricing controls, supply-chain integrity, and intellectual property protection, all under the scrutiny of agencies that govern biologic products; the most recent SEC disclosure was a Form 8-K filed Nov 1999. CIK 318771; view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025